Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

ViiV reports positive data for once-a-month HIV-1 therapy

The combination of cabotegravir and rilpivirine is being investigated for long-acting effect against HIV. Credit: ZEISS Microscopy.



  • ViiV reports positive Phase III data for once-a-month HIV-1 therapy

Go Top